Skip to content

Effect of Terminalia chebula gel in reducing the pain of patients with knee arthritis

Effect of Terminalia chebula gel in reducing the pain of patients with knee osteoarthritis: triple-blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240406061427N1
Enrollment
78
Registered
2024-07-15
Start date
2024-07-22
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Osteoarthritis, unspecified site

Interventions

Intervention 1: The first intervention group: 26 patients with knee osteoarthritis are selected. The first intervention group consumes 5% Halileh black topical gel 3 times a day locally on the knee. P

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: All patients with a definite diagnosis of osteoarthritis based on diagnostic criteria by a specialist doctor Age range between 45 and 75 years

Exclusion criteria

Exclusion criteria: The presence of simultaneous severe diseases such as metabolic and gastrointestinal diseases Severe infection Pregnancy and breastfeeding and abnormal liver tests History of old fracture or knee surgery Rheumatoid arthritis and seronegative and seropositive arthropathy History of intra-articular injection in the last 6 weeks

Design outcomes

Primary

MeasureTime frame
Knee pain. Timepoint: The first, third and the first, third and sixth weeks after the start of the intervention. Method of measurement: Based on VAS and WOMAC Patients' pain is measured through the VAS (Visual Analogue Scale) questionnaire and their performance through the Womac (Western Ontario and McMaster Universities Index) questionnaires.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Oboudiat

Shahre-kord University of Medical Sciences

navid.1999@yahoo.com+98 31 3650 5792

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026